PETACH TIKVA, ISRAEL / ACCESS Newswire / June 9, 2025 / Nanox Imaging announced that Ran Daniel, Chief Financial Officer, will be presenting at the Investor Summit Virtual taking place on June 10.
About Nanox Imaging
Nanox (NASDAQ:NNOX) is focused on driving the world's transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.
Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI for more accurate diagnostics and maintaining a clinically driven approach.
Event: Q2 Investor Summit
Presentation Time: June 10, 12:30 PM ET
Location: WEBCAST LINK
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who are undervalued, have a catalyst, and are undervalued.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
AccessNewswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESSWIRE
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.05 |
Daily Change: | -0.02 -0.39 |
Daily Volume: | 609,265 |
Market Cap: | US$295.530M |
June 05, 2025 May 22, 2025 April 17, 2025 March 31, 2025 March 26, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load